A Morbidity-Mortality and Remodeling Study With Valsartan

• Status: Unknown status
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jikei University School of Medicine
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure

Exclusion Criteria:

• Pregnancy

• Severe renal damage

• Severe liver damage

• Acute myocardial infarction